New guidelines have been produced for the management of primary biliary cholangitis, an infrequent but nonetheless important autoimmune liver disease. We provide a succient commentary and overview of the key features of disease management that arise from these recent guideline recommendations, with a focus on therapy with licensed agents (ursodeoxycholic acid and obeticholic acid) as well as personalised management of disease complications and associated symptoms.
- primary biliary cirrhosis
- ursodeoxycholic acid
- obeticholic acid
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors Drafting the manuscript: JCG. Drafting and revising the manuscript critically for important intellectual content: GMH.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests GMH has consulted for GSK, Novartis, Cymabay, Intercept, Falk, Gilead.
Provenance and peer review Not commissioned; externally peer reviewed.